Incidence of Guillain–Barré syndrome in South Korea during the early COVID-19 pandemic
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, S.A. | - |
dc.contributor.author | Hwang, J. | - |
dc.contributor.author | Lim, B.C. | - |
dc.contributor.author | Chae, S.A. | - |
dc.date.accessioned | 2023-09-27T06:41:43Z | - |
dc.date.available | 2023-09-27T06:41:43Z | - |
dc.date.issued | 2023-02 | - |
dc.identifier.issn | 1664-2295 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/67838 | - |
dc.description.abstract | Objectives: Guillain–Barré syndrome (GBS) is an immune-mediated polyradiculoneuropathy, often triggered by infection. We aimed to investigate how the incidence of GBS changed in the early stages of the coronavirus 2019 (COVID-19) pandemic when nationwide infections declined due to non-pharmaceutical interventions. Methods: We conducted a nationwide population-based retrospective GBS cohort study using data from the Health Insurance Review and Assessment Service of Korea. Patients with new-onset GBS were defined as those who were first hospitalized between 1 January 2016 and 31 December 2020 with an International Classification of Disease, 10th Revision code, for GBS (G61.0) as a primary diagnosis. The incidence of GBS in the pre-pandemic years (2016–2019) was compared with that in the first pandemic year (2020). Nationwide epidemiological data for infections were collected from the national infectious disease surveillance system. A correlation analysis was performed to determine the incidence of GBS and nationwide trends of various infections. Results: Overall, 3,637 new-onset GBS cases were identified. The age-standardized incidence of GBS in the first pandemic year was 1.10 (95% confidence interval, 1.01–1.19) per 100,000 persons. Compared to the first pandemic year, the incidence of GBS during the pre-pandemic years (1.33–1.68/100,000 persons/year) was significantly higher, with incidence rate ratios of 1.21–1.53 (P < 0.001). Nationwide cases of upper respiratory viral infections were significantly reduced in the first pandemic year; however, Campylobacter infections peaked in the summer of the pandemic. The nationwide epidemiology of parainfluenza virus, enterovirus, and Campylobacter infections correlated positively with GBS incidence. Conclusion: The overall GBS incidence decreased in the early stages of the COVID-19 pandemic, which can be attributed to the dramatic reduction in viral illnesses due to public measures. Copyright © 2023 Choi, Hwang, Lim and Chae. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Frontiers Media S.A. | - |
dc.title | Incidence of Guillain–Barré syndrome in South Korea during the early COVID-19 pandemic | - |
dc.type | Article | - |
dc.identifier.doi | 10.3389/fneur.2023.1125455 | - |
dc.identifier.bibliographicCitation | Frontiers in Neurology, v.14 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000943661500001 | - |
dc.identifier.scopusid | 2-s2.0-85149622641 | - |
dc.citation.title | Frontiers in Neurology | - |
dc.citation.volume | 14 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | Campylobacter | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Guillain-Barré syndrome | - |
dc.subject.keywordAuthor | nationwide infection | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordPlus | SPECTRUM | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.